In this direction, oncogenic driver mutations (also known as oncogene addiction), such as KRAS, EGFR, ALK, ROS1, BRAF, HER-2, MET, NTRK, and RET, mutations and inactivating mutations in tumor suppressor genes like TP53, KEAP1, STK11, and NF1, have been reported to promote mNSCLC disease [8, 209–212]. This evidence concerns the gene MET and neoplasm.